Gilead Sciences Inc. (GILD)

73.67
0.89 1.22
NASDAQ : Health Technology
Prev Close 72.78
Open 72.78
Day Low/High 72.18 / 74.01
52 Wk Low/High 64.27 / 89.54
Volume 7.25M
Avg Volume 6.23M
Exchange NASDAQ
Shares Outstanding 1.30B
Market Cap 95.13B
EPS 3.50
P/E Ratio 42.91
Div & Yield 2.28 (2.94%)

Latest News

How Gilead Call Prices Tripled Overnight

How Gilead Call Prices Tripled Overnight

These call buyers may have expected positive, bullish news in the coming weeks, on the belief that the pipeline for GILD is broad with a multitude of opportunities to serve as catalysts.

Gilead Sciences And Precision BioSciences Announce Collaboration To Develop Therapies Against Hepatitis B Virus Using ARCUS Genome Editing

Gilead Sciences And Precision BioSciences Announce Collaboration To Develop Therapies Against Hepatitis B Virus Using ARCUS Genome Editing

Gilead Sciences (Nasdaq: GILD) and Precision BioSciences announced today that the companies have entered into a strategic collaboration to develop therapies targeting the in vivo elimination of hepatitis B virus (HBV) with Precision's proprietary genome...

Gilead And Galapagos Announce Filgotinib Meets Primary And All Key Secondary Endpoints In First Phase 3 Study In Rheumatoid Arthritis

Gilead And Galapagos Announce Filgotinib Meets Primary And All Key Secondary Endpoints In First Phase 3 Study In Rheumatoid Arthritis

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that FINCH 2, a global, randomized, placebo-controlled, Phase 3 study of filgotinib, an investigational, selective JAK1 inhibitor, in adults with...

Gilead And Galapagos Announce TORTUGA Phase 2 Study Of Filgotinib In Ankylosing Spondylitis Achieves Primary Endpoint

Gilead And Galapagos Announce TORTUGA Phase 2 Study Of Filgotinib In Ankylosing Spondylitis Achieves Primary Endpoint

Gilead Sciences, Inc. (NASDAQ:GILD) and Galapagos NV (Euronext & NASDAQ:GLPG) today announced that the randomized, placebo-controlled Phase 2 TORTUGA study of filgotinib, an investigational, selective JAK1 inhibitor, achieved its primary efficacy endpoint...

Gilead Sciences To Present At The Morgan Stanley Global Healthcare Conference On Wednesday, September 12

Gilead Sciences To Present At The Morgan Stanley Global Healthcare Conference On Wednesday, September 12

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that John F.

Laura Hamill - Executive Vice President, Worldwide Commercial Operations, Gilead Sciences (Photo: Business Wire)

Laura Hamill - Executive Vice President, Worldwide Commercial Operations, Gilead Sciences (Photo: Business Wire)

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Laura Hamill will join the company as Executive Vice President, Worldwide Commercial Operations, and will become a member of Gilead's senior leadership team.

Yescarta® (Axicabtagene Ciloleucel) Receives European Marketing Authorization For The Treatment Of Relapsed Or Refractory DLBCL And PMBCL, After Two Or More Lines Of Systemic Therapy

Yescarta® (Axicabtagene Ciloleucel) Receives European Marketing Authorization For The Treatment Of Relapsed Or Refractory DLBCL And PMBCL, After Two Or More Lines Of Systemic Therapy

Kite, a Gilead Company (Nasdaq: GILD), today announced that the European Commission (EC) has granted Marketing Authorization for Yescarta ® (axicabtagene ciloleucel) as a treatment for adult patients with relapsed or refractory diffuse large B-cell...

Here's Why You Should Invest in Immunotherapy Companies

Here's Why You Should Invest in Immunotherapy Companies

Immunotherapy may be the future of fighting cancer and companies are racing to capitalize on that. We spoke with the CEO of the Damon Runyon Cancer Research Foundation to find out why.

Gilead Sciences Announces Executive Promotions

Gilead Sciences Announces Executive Promotions

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Gregg Alton has been appointed Chief Patient Officer, a newly created role that will facilitate access to the company's medicines and increase focus on reaching patients.

3 Cheap Healthcare Stocks That Won't Make Your Portfolio Sick

3 Cheap Healthcare Stocks That Won't Make Your Portfolio Sick

The healthcare space continues to be ripe for investment opportunity. Here are three stocks that won't make your portfolio sick.

China National Drug Administration Approves Gilead's Genvoya® (Elvitegravir, Cobicistat, Emtricitabine And Tenofovir Alafenamide), A Single Tablet Regimen For The Treatment Of HIV-1 Infection

China National Drug Administration Approves Gilead's Genvoya® (Elvitegravir, Cobicistat, Emtricitabine And Tenofovir Alafenamide), A Single Tablet Regimen For The Treatment Of HIV-1 Infection

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the China National Drug Administration (CNDA) has approved Genvoya ® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg or E/C/F/TAF) for the treatment of HIV-1...

Why Investors Should Favor Smaller Biotech Companies

Why Investors Should Favor Smaller Biotech Companies

Small and mid-cap biotech firms are driving innovation in the sector. Experts explain why investors should take notice.

Gilead's Earnings Fail to Impress

Gilead's Earnings Fail to Impress

The company is losing sales aggressively as it fails to create any business substantial enough to make up for the shrinking sales in its Hepatitis C drugs.

Gilead Sciences Announces Third Quarter 2018 Dividend

Gilead Sciences Announces Third Quarter 2018 Dividend

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared a cash dividend of $0.

Gilead Sciences Announces Second Quarter 2018 Financial Results

Gilead Sciences Announces Second Quarter 2018 Financial Results

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter ended June 30, 2018.

Gilead Sciences Announces CEO John F. Milligan To Step Down

Gilead Sciences Announces CEO John F. Milligan To Step Down

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that John F.

Buy These 3 Risky Biotech Stocks

Buy These 3 Risky Biotech Stocks

Is the pharma sector fever heating up in 2H18? Drug investors, get ready as there could be some good trades to be made.

Gilead Announces New Data On The Impact Of Truvada® (Emtricitabine And Tenofovir Disoproxil Fumarate) For Pre-Exposure Prophylaxis (PrEP) On The Number Of HIV Diagnoses In The United States

Gilead Announces New Data On The Impact Of Truvada® (Emtricitabine And Tenofovir Disoproxil Fumarate) For Pre-Exposure Prophylaxis (PrEP) On The Number Of HIV Diagnoses In The United States

Gilead Sciences, Inc. (NASDAQ: GILD) today announced results of a retrospective nationwide analysis of the impact of Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets) for pre-exposure prophylaxis (PrEP) use across all 50 U.

Kite And Gadeta Announce Strategic Collaboration To Advance Gamma Delta T Cell Receptor Technology For Solid Tumors

Kite And Gadeta Announce Strategic Collaboration To Advance Gamma Delta T Cell Receptor Technology For Solid Tumors

Kite, a Gilead Company (Nasdaq: GILD), and Gadeta B.V.

Biotech's Coming Back to Life: Cramer's 'Off the Charts'

Biotech's Coming Back to Life: Cramer's 'Off the Charts'

Some beaten up biotech names are finally coming back to life. Here's a look at the technical analysis.

Market Refuses To Go Lower: Cramer's 'Mad Money' Recap (Tuesday 7/17/18)

Market Refuses To Go Lower: Cramer's 'Mad Money' Recap (Tuesday 7/17/18)

Investors have never gone wrong buying Netflix on the dips. Jim Cramer tells you what to make of the 'FANG Musketeers.'

Gilead Sciences To Release Second Quarter 2018 Financial Results On Wednesday, July 25, 2018

Gilead Sciences To Release Second Quarter 2018 Financial Results On Wednesday, July 25, 2018

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2018 financial results will be released on Wednesday, July 25, after the market closes.

Michael Amoroso To Join Kite As Senior Vice President And Head Of Worldwide Commercial, Cell Therapy

Michael Amoroso To Join Kite As Senior Vice President And Head Of Worldwide Commercial, Cell Therapy

Kite, a Gilead Company (NASDAQ: GILD), announced today that Michael Amoroso will join the company as Senior Vice President and Head of Worldwide Commercial, Cell Therapy.

Chart of the Day: Gilead Sciences

GILD is finally showing some robust price action.

Biotech Stocks Rally on Biogen's Landmark Test

Biotech Stocks Rally on Biogen's Landmark Test

Investors might be finally recognizing the hidden value of the firms' drug research and development.

Gilead Sciences Is Displaying a Bullish Long-Term Pattern

Gilead Sciences Is Displaying a Bullish Long-Term Pattern

This biotech's weekly chart is very encouraging.

European CHMP Adopts Positive Opinion For Yescarta® (axicabtagene Ciloleucel) For The Treatment Of Relapsed Or Refractory DLBCL And PMBCL, After Two Or More Lines Of Systemic Therapy

European CHMP Adopts Positive Opinion For Yescarta® (axicabtagene Ciloleucel) For The Treatment Of Relapsed Or Refractory DLBCL And PMBCL, After Two Or More Lines Of Systemic Therapy

Kite, a Gilead Company (Nasdaq: GILD), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the company's Marketing Authorization Application (MAA) for Yescarta ®...

TheStreet Quant Rating: C (Hold)